Manulife (Manufacturers Life Insurance)
CLDX icon

Manulife (Manufacturers Life Insurance)’s Celldex Therapeutics CLDX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.47M Buy
77,772
+2,642
+4% +$72K ﹤0.01% 1413
2025
Q4 		$2.01M Sell
75,130
-11,944
-14% -$315K ﹤0.01% 1517
2025
Q3 		$2.25M Sell
87,074
-37,472
-30% -$868K ﹤0.01% 1470
2025
Q2 		$2.53M Buy
124,546
+29,761
+31% +$579K ﹤0.01% 1411
2025
Q1 		$1.72M Sell
94,785
-9,591
-9% -$214K ﹤0.01% 1548
2024
Q4 		$2.64M Sell
104,376
-1,401
-1% -$38.1K ﹤0.01% 1445
2024
Q3 		$3.6M Sell
105,777
-24,010
-18% -$915K ﹤0.01% 1351
2024
Q2 		$4.8M Buy
129,787
+243
+0.2% +$9.17K ﹤0.01% 1183
2024
Q1 		$5.44M Buy
129,544
+86,117
+198% +$3.54M 0.01% 1157
2023
Q4 		$1.72M Sell
43,427
-6,405
-13% -$188K ﹤0.01% 1522
2023
Q3 		$1.37M Buy
49,832
+4,666
+10% +$146K ﹤0.01% 1567
2023
Q2 		$1.53M Sell
45,166
-15,912
-26% -$536K ﹤0.01% 1491
2023
Q1 		$2.2M Buy
61,078
+2,427
+4% +$105K ﹤0.01% 1376
2022
Q4 		$2.63M Buy
58,651
+4,187
+8% +$149K ﹤0.01% 1313
2022
Q3 		$1.54M Buy
54,464
+4,331
+9% +$133K ﹤0.01% 1452
2022
Q2 		$1.38M Sell
50,133
-13,378
-21% -$389K ﹤0.01% 1514
2022
Q1 		$2.19M Buy
63,511
+40,225
+173% +$1.29M ﹤0.01% 1476
2021
Q4 		$903 Sell
23,286
-93
-0.4% -$4.05K ﹤0.01% 1899
2021
Q3 		$1.26M Buy
23,379
+1,244
+6% +$58.4K ﹤0.01% 1692
2021
Q2 		$740K Buy
+22,135
New +$608K ﹤0.01% 2168
2018
Q3 		– Sell
-273
Closed -$2K – 3077
2018
Q2 		$2K Sell
273
-6,581
-96% -$88K ﹤0.01% 4196
2018
Q1 		$239K Sell
6,854
-121
-2% -$4.69K ﹤0.01% 2882
2017
Q4 		$297K Buy
6,975
+384
+6% +$16.4K ﹤0.01% 2709
2017
Q3 		$283K Sell
6,591
-45
-0.7% -$1.69K ﹤0.01% 2701
2017
Q2 		$246K Buy
6,636
+1,424
+27% +$63K ﹤0.01% 2844
2017
Q1 		$282K Buy
5,212
+608
+13% +$31.7K ﹤0.01% 2590
2016
Q4 		$244K Buy
4,604
+79
+2% +$4.49K ﹤0.01% 2631
2016
Q3 		$275K Buy
4,525
+73
+2% +$4.55K ﹤0.01% 2534
2016
Q2 		$294K Buy
4,452
+58
+1% +$3.68K ﹤0.01% 2405
2016
Q1 		$237K Buy
4,394
+81
+2% +$9.11K ﹤0.01% 2481
2015
Q4 		$1.01K Buy
4,313
+44
+1% +$9.59K ﹤0.01% 1620
2015
Q3 		$675 Sell
4,269
-7,142
-63% -$2.02M ﹤0.01% 1810
2015
Q2 		$4.32K Buy
11,411
+224
+2% +$89K 0.01% 1125
2015
Q1 		$4.68K Sell
11,187
-2,998
-21% -$1.07M 0.01% 1072
2014
Q4 		$3.88K Buy
14,185
+10,303
+265% +$2.56M 0.01% 1088
2014
Q3 		$754 Buy
3,882
+86
+2% +$18.7K ﹤0.01% 1741
2014
Q2 		$929K Sell
3,796
-665
-15% -$150K ﹤0.01% 1629
2014
Q1 		$1.18K Sell
4,461
-8,827
-66% -$3.38M ﹤0.01% 1528
2013
Q4 		$4.83K Sell
13,288
-79
-0.6% -$30.4K 0.01% 1028
2013
Q3 		$7.1K Sell
13,367
-241
-2% -$82.6K 0.01% 783
2013
Q2 		$3.19M Buy
+13,608
New +$2.68M 0.01% 1084

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s CLDX Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Celldex Therapeutics (CLDX) stake by 3.5% in Q1 2026, buying an estimated $72K and bringing the position to 77,772 shares worth $2.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

Manulife (Manufacturers Life Insurance) first reported a position in CLDX in Q2 2013 and has held it in 41 quarters since. The position peaked at $5.44M in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 77,772 shares of Celldex Therapeutics worth $2.47M as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 2,642 Celldex Therapeutics shares in Q1 2026, an estimated $72K.
  • Celldex Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1413 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 41 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Celldex Therapeutics position peaked at $5.44M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.